Best Drug Manufacturers - Specialty & Generic Stocks for 2026
Specialty and generic drugmakers compound on volume and niche pricing rather than branded margins, so Valuation leads with Health covering debt service and FDA exposure.
Specialty and Generic Drug Manufacturers earn lower gross margins than big pharma but compound on volume and niche pricing. Composite ranking uses the Valuation pillar as the primary signal (the cohort is structurally cheaper than branded pharma) with Health pillar (debt service, FDA exposure) as the safety floor.
Data as of (updated daily)
Top 20 Drug Manufacturers - Specialty & Generic stocks by composite score
| # | Ticker | Name | Composite |
|---|---|---|---|
| 1 | 002001.SHE | Zhejiang Nhu Co Ltd | 77.6 |
| 2 | 300573.SHE | Shenyang Xingqi Pharmaceutical Co Ltd | 76.8 |
| 3 | NBIX.US | Neurocrine Biosciences Inc | 75.7 |
| 4 | 000989.SHE | Jiuzhitang Co Ltd | 75.7 |
| 5 | N1BI34.SA | Neurocrine Biosciences Inc. | 75.4 |
| 6 | 0950.HK | Lee’s Pharmaceutical Holdings Ltd | 74.3 |
| 7 | 002365.SHE | Qianjiang Yongan Pharmaceutical Co Ltd | 73.4 |
| 8 | 096760.KO | Jw Holdings | 73.3 |
| 9 | 600276.SHG | Jiangsu Hengrui Medicine Co Ltd | 72.0 |
| 10 | 000423.SHE | Shan Dong Dong-E E-Jiao Co Ltd | 71.8 |
| 11 | 002412.SHE | Hunan Hansen Pharmaceutical Co Ltd | 71.0 |
| 12 | ANIP.US | ANI Pharmaceuticals Inc | 70.7 |
| 13 | 600867.SHG | Tonghua Dongbao Pharmaceutical Co Ltd | 70.4 |
| 14 | 603998.SHG | Hunan Fangsheng Pharm Co Ltd | 70.3 |
| 15 | 002826.SHE | Tibet Aim Pharm Inc | 70.3 |
| 16 | 600079.SHG | Humanwell Healthcare Group Co Ltd | 70.0 |
| 17 | 600211.SHG | Tibet Rhodiola Pharmaceutical Holding Co | 69.7 |
| 18 | 8049.HK | Jilin Province Huinan Changlong Bio-pharmacy Co Ltd | 69.2 |
| 19 | VENUSREM.NSE | Venus Remedies Limited | 69.0 |
| 20 | 002020.SHE | Zhejiang Jingxin Pharmaceutical Co Ltd | 68.6 |
Want to drill into Drug Manufacturers - Specialty & Generic stocks?
The full screener applies the Drug Manufacturers - Specialty & Generic industry filter and lets you stack 30+ more filters on top: market cap, country, dividend yield, and the four pillar scores.
Open in screener →Explore related pages
Drug Manufacturers - Specialty & Generic by strategy
Drug Manufacturers - Specialty & Generic by country
Other industries in Healthcare
Parent sector
Recent Drug Manufacturers - Specialty & Generic insights
- Analysis
NVIDIA $4.58T Market Cap, FY25 Revenue $130.5B, ROE 109.42%, P/E 57.64x
NVIDIA leads the group with a $4.58T market cap and an exceptional 109.42% ROE while reporting FY25 revenue of $130.5B (up 114%) and a P/E of 57.64.
- Sector Spotlight
Healthcare Sector Averages 51/100 Score, 31.2x P/E, -17.6% ROE
Healthcare sector averages 51/100 score, P/E 31.2, and -17.6% ROE, signaling broad profitability issues despite premium valuations.
- Sector Spotlight
Healthcare Averages 31.2x Earnings, NUTX at 2.38x, GSK 13.01x
Healthcare sector averages 52/100 valuation score with P/E of 31.2, trading 50% above S&P 500 norms, yet quality leaders like NUTX (P/E 2.38) and GSK (P/E 13.01) offer deep discounts.
Methodology: How we score stocks. Data refreshed nightly around 03:30 ET. This page lists the top 20 by composite score; use the screener for the full ranked list.